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Abstract: Background: Chronic pain conditions, especially osteoarthritis (OA), are as common in
individuals with Alzheimer's disease (AD) as in the general elderly population, which
results in detrimental impact on patient's quality of life. However, alteration in
perception of pain in AD coupled with deteriorating ability to communicate pain
sensations often result in under-diagnosis and inappropriate management of pain.
Therefore, a better understanding of mechanisms in chronic pain processing in AD is
needed. Here, we explored development and progression of OA pain and effect of
analgesics in a transgenic mouse model of AD.
Methods: Unilateral OA pain was induced chemically, via an intra-articular injection of
monosodium iodoacetate (MIA) in the left knee joint of AD-mice (TASTPM) and age-
and-gender-matched C57BL/6J (WT). Pharmacological and biochemical assessments
were conducted in plasma and spinal cord tissue.
Results: MIA resulted in hind paw mechanical hypersensitivity (allodynia), initiating on
day 3, in TASTPM and WT controls. However, from 14 to 28 days, TASTPM displayed
partial attenuation of allodynia and diminished spinal microglial response compared to
WT controls. Naloxone, an opioid antagonist, re-established allodynia levels as
observed in the WT group. Morphine, an opioid agonist, induced heightened analgesia
in AD-mice whilst gabapentin was devoid of efficacy. TASTPM exhibited elevated
plasma level of β-endorphin post MIA which correlated with the impaired allodynia.
Conclusions: These results indicate an alteration of the opioidergic system in TASTPM
as possible mechanisms underlying impaired persistent pain sensitivity in AD. This
work provides basis for re-evaluation of opioid analgesic-use for management of pain
in AD.
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Abstract  
Background: Chronic pain conditions, especially osteoarthritis (OA), are as common in 
individuals with Alzheimer’s disease (AD) as in the general elderly population, which results 
in detrimental impact on patient’s quality of life. However, alteration in perception of pain in 
AD coupled with deteriorating ability to communicate pain sensations often result in under-
diagnosis and inappropriate management of pain. Therefore, a better understanding of 
mechanisms in chronic pain processing in AD is needed. Here, we explored development and 
progression of OA pain and effect of analgesics in a transgenic mouse model of AD. 
Methods: Unilateral OA pain was induced chemically, via an intra-articular injection of 
monosodium iodoacetate (MIA) in the left knee joint of AD-mice (TASTPM) and age-and-
gender-matched C57BL/6J (WT). Pharmacological and biochemical assessments were 
conducted in plasma and spinal cord tissue.   
Results: MIA resulted in hind paw mechanical hypersensitivity (allodynia), initiating on day 
3, in TASTPM and WT controls. However, from 14 to 28 days, TASTPM displayed partial 
attenuation of allodynia and diminished spinal microglial response compared to WT controls. 
Naloxone, an opioid antagonist, re-established allodynia levels as observed in the WT group. 
Morphine, an opioid agonist, induced heightened analgesia in AD-mice whilst gabapentin was 
devoid of efficacy. TASTPM exhibited elevated plasma level of β-endorphin post MIA which 
correlated with the impaired allodynia.  
Conclusions: These results indicate an alteration of the opioidergic system in TASTPM as 
possible mechanisms underlying impaired persistent pain sensitivity in AD. This work provides 
basis for re-evaluation of opioid analgesic-use for management of pain in AD.   
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Abstract  
Background: Chronic pain conditions, especially osteoarthritis (OA), are as common in 
individuals with Alzheimer’s disease (AD) as in the general elderly population, which results 
in detrimental impact on patient’s quality of life. However, alteration in perception of pain in 
AD coupled with deteriorating ability to communicate pain sensations often result in under-
diagnosis and inappropriate management of pain. Therefore, a better understanding of 
mechanisms in chronic pain processing in AD is needed. Here, we explored development and 
progression of OA pain and effect of analgesics in a transgenic mouse model of AD. 
Methods: Unilateral OA pain was induced chemically, via an intra-articular injection of 
monosodium iodoacetate (MIA) in the left knee joint of AD-mice (TASTPM) and age-and-
gender-matched C57BL/6J (WT). Pharmacological and biochemical assessments were 
conducted in plasma and spinal cord tissue.   
Results: MIA resulted in hind paw mechanical hypersensitivity (allodynia), initiating on day 
3, in TASTPM and WT controls. However, from 14 to 28 days, TASTPM displayed partial 
attenuation of allodynia and diminished spinal microglial response compared to WT controls. 
Naloxone, an opioid antagonist, re-established allodynia levels as observed in the WT group. 
Morphine, an opioid agonist, induced heightened analgesia in AD-mice whilst gabapentin was 
devoid of efficacy. TASTPM exhibited elevated plasma level of β-endorphin post MIA which 
correlated with the impaired allodynia.  
Conclusions: These results indicate an alteration of the opioidergic system in TASTPM as 
possible mechanisms underlying impaired persistent pain sensitivity in AD. This work 
provides basis for re-evaluation of opioid analgesic-use for management of pain in AD.   
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Significance Statement 
This study shows attenuated pain-like behaviour in a transgenic mouse model of Alzheimer's 
disease due to alterations in the opioidergic system and central plasticity mechanisms of 
persistent pain.  
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Introduction  
Alzheimer’s disease (AD) is the most common cause of dementia (> 60% of dementia) in the 
elderly population. Clinically it is characterised by a global cognitive deficit ranging from loss 
of memory to impaired judgement and reasoning (Tanzi and Bertram 2001). Experience of pain 
is a key contributor to challenge of care in AD individuals and is often associated with age-
related medical comorbidities, commonly musculoskeletal conditions such as osteoarthritis 
(OA).   
OA is the most common age-related musculoskeletal condition affecting the elderly population 
over the age of 50 (Litwic et al., 2013). Clinical symptoms are primarily chronic pain coupled 
with joint stiffness and dysfunction (Hunter et al., 2008). Due to an incomplete understanding 
of the underlying mechanisms, there are no cure or disease modifying drugs, at present. 
Currently the best treatment options are physiotherapy, pain relief (i.e. paracetamol, non-
steroidal anti-inflammatory drugs (NSAIDs), and opiates) and surgical joint replacement 
(Hunter and Felson 2006). 
The cause and incidence of chronic pain conditions, in particular OA, are as common in 
individuals with AD as in the general elderly population. Despite availability of pain treatment 
options, assessment and treatment of pain in AD is often difficult, which has a negative impact 
on the quality of life (Corbett et al., 2012). Under-treated and inappropriate prescribing in this 
patient group results in reduced mobility, muscle weakness and falls, which consequently has 
a major detrimental impact on quality of life and is a key contributor to the presentation of 
neuropsychiatric symptoms such as aggression and mood disorders (Ballard et al., 2014; 
Rajkumar et al., 2017). 
It remains unclear whether differences observed in reporting and management of pain are a 
result of impaired memory and ability to communicate; and/or the perception of pain is altered 
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due to progressive degeneration of cortical and sub-cortical regions involved in processing and 
transmission of nociceptive information (Hyman et al., 1984; Scherder and Bouma 2000). AD 
associated neuropathological hallmarks, namely, extracellular β-amyloid (Aβ) plaques and 
intracellular neurofibrillary tangles (NFT), accompanied by neuroinflammation have been 
detected in regions involved in pain processing, namely the spinal cord and the thalamus 
(Aman et al., 2016; Rub et al., 2002; Schmidt et al., 2001). To date, difficulties in assessment 
of pain in individuals with cognitive-impairments has been identified, however there is a lack 
of understanding of underlying mechanisms of pain in this susceptible population (Ballard et 
al., 2009; Corbett et al., 2012).  
Therefore, a better understanding of the pathophysiological mechanisms underlying 
development and progression of OA is essential for improving the clinical management of this 
chronic pain condition in patients with AD. Here, we assessed development of chemically 
induced OA pain, via an intra-articular administration of monosodium iodoacetate (MIA), in 
the double-mutant TASTPM transgenic mouse model of AD (Howlett et al., 2004; Ogbonna et 
al., 2013). The TASTPM transgenic mouse strain carries mutant versions of the amyloid 
precursor protein (APPswe) and presenilin-1 (PS1.M146V) associated with familial forms of 
AD (Howlett et al., 2004). Histological and behavioural analysis of these animals has identified 
pathological characteristics and cognitive alterations from 3 and 6 months of age respectively 
that reflect some aspects of the pathological changes and cognitive defects observed in people 
with AD (Howlett et al., 2008; Howlett et al., 2004). Specifically, we characterised pain-like 
behaviour and associated pathological changes in the periphery and the spinal cord. In addition, 
we evaluated the effectiveness of commonly used analgesics in alleviating MIA-induced 
nociceptive hypersensitivity in TASTPM and age and gender-matched non-transgenic controls. 
Materials and methods  
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Animals 
Experiments were performed on 6-8 months old adult male and female heterozygous double-
mutant TASTPM transgenic mouse model of AD obtained from GlaxoSmithKline (GSK) 
(Aman et al., 2016). The TASTPM were generated using TAS10 transgenic mice expressing 
the Swedish mutant human amyloid precursor protein (APP) (695-aa isoform) under the control 
of the murine Thy-1 promoter and transgenic mice over expressing presenilin-1 M146V 
mutation (TPM) driven through the murine Thy-1 promoter (Howlett et al., 2004; Richardson 
et al., 2003). Briefly, TAS10 (Thy-1.APPswe) mice were generated and backcrossed onto a 
pure C57BL/6 background before being crossed with TPM (Thy-1.PSEN-1.M146V) mice to 
produce heterozygous double mutant TASTPM mice. Age and gender-matched C57BL/6J 
(WT) obtained from Charles River were used as controls. All animals were housed in the 
Biological Services Unit, King’s College London; maintained in 12 hours day/night cycle with 
ad libitum access to food and water; and were allowed acclimatisation for 7 days prior to 
behavioural experiments. All experiments were conducted in accordance with United Kingdom 
Home Office Regulations (Animal Scientific Procedures Act, 1986). Experimental study 
groups were randomized, and experiments were performed by an observer unaware of 
treatments. 
Monosodium iodoacetate (MIA) model of osteoarthritis pain 
Unilateral knee joint osteoarthritis was induced by a single intra-articular injection of 10 µl 
sterile 0.9% saline containing 1 mg MIA (Sigma, UK) into the left knee using a 28G needle 
and a Hamilton syringe, under isoflurane/O2 inhalation anaesthesia (Ogbonna et al., 2013; 
Pitcher et al., 2016). Control mice received an intra-articular injection of sterile saline (10 μl). 
Behavioural testing 
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Weight bearing changes were assessed as a measure of ongoing primary pain associated 
hypersensitivity. Weight bearing was assessed using an incapacitance tester (Linton 
Instrumentation, UK) as previously described (Ogbonna et al., 2013). Briefly, mice were 
placed in a Perspex enclosure so that each hind paw is rested on separate transducer pads. Once 
the mice were settled and in correct position, the force exerted by each hind limb was measured 
over a period of 1 second. The first 3 sets of 1 second measurements were taken and then 
averaged. These values were then transformed to give the percentage of total hind limb weight 
borne on the ipsilateral side using the formula: 
𝑊𝑒𝑖𝑔ℎ𝑡 𝐵𝑜𝑟𝑛𝑒 =  
𝐼𝑝𝑠𝑖𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑏𝑜𝑟𝑛𝑒 × 100
𝐼𝑝𝑠𝑖𝑙𝑡𝑒𝑟𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑏𝑜𝑟𝑛𝑒 + 𝐶𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑏𝑜𝑟𝑛𝑒
 
A value of 50% represents equal weight distributed across both hind limbs, whereas a value of 
less than 50% was indicative of reduced weight borne on the ipsilateral hind limb.    
Mechanical withdrawal thresholds were assessed by calibrated von Frey monofilaments 
(0.007g – 1.00g) application to the plantar surface of the hind paw. The 50% paw withdrawal 
threshold (PWT) was determined according to the ‘up-down’ method (Aman et al., 2016).  
Behaviour was assessed prior to (baseline observations) and at regular intervals: 3, 7, 10, 14, 
17, 21, 24 and 28 days following MIA/saline injection.  
Analgesic testing 
Celecoxib (30 mg/kg) was purchased from Sigma and dissolved in 1% (w/v) methyl cellulose 
solution. Paracetamol (acetaminophen; 300 mg/kg) and morphine sulfate (6 mg/kg) were 
obtained from Sigma and were dissolved in sterile saline. Gabapentin (60 mg/kg) was supplied 
by LKT Laboratories inc. and was dissolved in dH2O.  Drugs were administrated either 
subcutaneously (s.c.: morphine) or orally (p.o.: celecoxib, paracetamol and gabapentin). 
8 
 
Celecoxib was administrated up to day 7; and paracetamol, morphine and gabapentin were 
delivered between days 10 to 28 after MIA injection in a different set of animals. On the day 
of testing pre-dose behavioural readings were recorded and the effect of the drug administrated 
(post-dose) mechanical thresholds were monitored at 30 minutes (paracetamol), 1 hour 
(celecoxib and morphine) or 3 hours (gabapentin). Data for drug effects were expressed as 
mean grams threshold, calculated as post-dose–pre-dose value. 
Naloxone administration 
Naloxone hydrochloride (1mg/kg) was obtained from Sigma and dissolved in sterile saline. 
Naloxone hydrochloride was administered via an intra-peritoneal (i.p.) injection on day 24 post 
MIA injection. On the day of testing pre-dose behavioural readings were recorded and the 
effect of the drugs administrated were monitored over a period of 3 hours, with mechanical 
hypersensitivity tests carried out at 30 minutes, 90 minutes, and 180 minutes after 
administration. 
Perfusion 
Four weeks after MIA injection, mice were terminally anaesthetised with an overdose of 
sodium pentobarbital (~150mg/kg body weight, Euthatal, Merial Animal Health, UK) and 
perfused transcardially with heparinised (1 U/ml) sterile saline followed by 4% 
paraformaldehyde (PFA, Sigma, UK) fixative solution containing 1.5% picric acid (Sigma, 
UK) in phosphate buffer (PB, 0.1M, pH 7.4).  
Knee histology 
The knees were dissected out, and surrounding muscle was trimmed. Tissues were post-fixed 
72 hours in 4% PFA, placed in decalcifying solution containing 10% (w/v) formic acid (VWR, 
UK) for 72 hours, embedded in paraffin and sagittal sections (6 μm) were cut using a 
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microtome that were mounted onto Superfrost Plus microscope slides (BDH, UK). Sections 
were de-waxed in xylene, rehydrated in ethanol, followed by washing in dH2O before staining 
with either in 0.05% (v/v) toluidine blue dye (pH 4, Sigma, UK) or Gill’s (2) haematoxylin and 
eosin (H&E, Sigma, UK). Sections were subsequently rapidly dehydrated, cleared in xylene, 
and coverslipped using dibutylphthalate in xylene mounting medium (DPX, Sigma, UK). The 
knee joint histology was visualised using Zeiss microscope (Axioskop) and images were 
captured using Zeiss Axiocam MRc and the software Axiovision Release 4.6.  
Immunohistochemistry 
Spinal cords (L3-L6) were removed and immersion-fixed in 4% PFA fixative solution 
containing 1.5% picric acid for 24 hours at 4°C. Subsequently, spinal cords were cryoprotected 
in a solution of 20% sucrose in PB at 4°C for at least 48 hours and subsequently embedded in 
optimum cutting temperature (OCT, BDH, UK) medium and then snap-frozen using liquid 
nitrogen and stored at -80°C. Transverse spinal cord sections were cut (20 μm thick) using a 
cryostat and thaw mounted onto Superfrost Plus microscope slides. 
Immunofluorescence was conducted on frozen slide-mounted 20 μm transverse spinal cord 
sections. Briefly, sections were blocked in PBS with 1% (w/v) bovine serum albumin (BSA, 
Sigma, UK), 0.2% (w/v) sodium azide (Sigma, UK) and 0.1% Triton X-100 (BDH, UK) prior 
to an overnight incubation with the primary antibody rabbit anti-phospho-p38 (p-p38, 1:100, 
Cell Signaling). Sections were then incubated for 1 hour with biotinylated donkey anti-rabbit 
(1:400; Jackson ImmunoResearch) followed by peroxidase containing avidin-biotin complex 
(Vectastatin® ABC Kit, Vector) and bitotinylated tyramide (NEN, Life Science Products), 
which was detected with Extra-Avidin conjugated FITC (1:500, Sigma). Sections were then 
incubated overnight with rabbit anti-ionized calcium binding adaptor molecule 1 (IBA1, 
1:1000, Wako) followed by Alexa Fluor 546-conjugated donkey anti-rabbit antibody (1:1000, 
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Molecular Probes). Sections then coverslipped with Vectashield Mounting Medium containing 
nuclear marker 4’,6-diamidino-2-phenylindole·2HCl (DAPI; Vector Laboratories, UK). All 
steps were conducted at room temperature and all antibody solutions were prepared in PBS 
with 1% BSA, 0.1% Triton X-100 and 0.2% sodium azide. The specificity of immunoreactivity 
was confirmed by omitting the primary antibody; and the immunofluorescent staining was 
visualized using Zeiss microscope (Imager.Z1) and images were captured using Zeiss 
AxioCam MRm and the software Axiovision Release 4.8.2. (Zeiss, UK). 
Quantitative assessment of immunostaining 
Quantitative assessment of number of IBA1 immunopositive microglial cells that also 
expressed p-p38 immunoreactivity in the spinal cord were calculated by counting the frequency 
of IBA1 immunopositive cells in a defined region of 4 × 104 μm2 placed onto the superficial 
laminae of the dorsal horn (laminae I-III) using Axiovision LE 4.8 software. Three L3-L5 
sections at least 200 μm apart from each animal were randomly selected from at least four 
animals per experimental group. 
Enzyme immuno-assay (EIA) 
Four weeks after MIA injection, mice were terminally anaesthetised with an overdose of 
sodium pentobarbital (~150mg/kg body weight) and using a 25G needle attached to 1ml 
syringe a cardiac puncture was performed and blood was drawn into heparin-coated beads 
containing tubes. Samples were immediately placed on ice for half an hour prior centrifuging 
at 13,000rpm for 20 minutes at 4°C and the supernatant (plasma) was collected, which was 
assayed for β-endorphin content by EIA using the endorphin, beta (mouse, bovine, ovine, 
camel) - EIA kit (Phoenix Pharmaceuticals). The peptide standards (0.01ng/ml - 100ng/ml), 
assay buffer (total binding), or positive control were run in duplicate according to the 
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manufacturer’s protocol. The optical density of each well was determined at a wavelength of 
450 nm. 
Statistical analysis 
The data were analysed using SigmaPlot 12.5 (Systat Software, San Jose, CA). The statistical 
tests performed and the numbers of animals used are displayed in the results section and within 
the figure legends. Where data were not normally distributed, the appropriate non-parametric 
test was applied. Graphs were generated using GraphPad Prism 5 (Graphpad Software Inc., 
San Diego, USA). All data are presented as mean ± standard error mean (SEM) and a 
probability value less than 0.05 (p < 0.05) was considered statistically significant. 
Results 
Weight asymmetry absent in TASTPM following MIA injection 
As previously reported (Ogbonna et al., 2013), WT mice injected with intra-articular MIA 
displayed significant reduced weight borne on the ipsilateral hind limb compared to their 
respective saline control on day 3 which remains consistently different up till day 28. In 
contrast, TASTPM mice injected with MIA did not exhibit any significant weight asymmetry 
compared to the saline injected TASTPM group throughout the course of the study (Fig. 1A). 
An area under the curve (AUC) analysis revealed significantly reduced weight borne on the 
ipsilateral hind limb by only MIA injected WT mice compared to their respective saline group 
during both the early (day 0 – day 7) and late (day 10 – day 28) phases (Fig. 1B-D). Thus, 
weight asymmetry was observed to be absent in the TASTPM mouse model of AD following 
an intra-articular injection of MIA.   
Impaired maintenance of MIA-induced mechanical hypersensitivity in TASTPM 
mice 
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MIA injection into the mouse knee is associated with referred mechanical hypersensitivity in 
the ipsilateral hind paw (Ogbonna et al., 2013). Here, this observation was confirmed in WT 
mice with a significant reduction in mechanical withdrawal thresholds initiating on day 3, 
peaking on day 7, and lasting up to day 28 as compared to respective saline controls (Fig. 2A). 
We observed that mechanical hypersensitivity developed comparably in TASTPM; however 
the AD mice exhibited a partial recovery demonstrated by significantly higher mechanical 
thresholds than in WT mice from day 21 post MIA injection (Fig. 2A). Analysis of AUC 
demonstrated the mechanical withdrawal thresholds of MIA-injected TASTPM mice were 
higher than WT thresholds, in particular during the late phase between days 10 to 28 (Fig. 2B-
D).  
These data demonstrate that the extent of MIA-induced pain-like behaviour is attenuated in 
TASTPM AD mice. Specifically, TASTPM fail to maintain late phase of mechanical 
hypersensitivity which is postulated to represent the established phase of the model. 
MIA-induced cartilage degradation 
Histological examination of toluidine blue staining of knee joints 28 days following intra-
articular injections demonstrate that saline-treated knees from both WT and TASTPM mice 
have intact and smooth articular surfaces (Fig. 3A and C). MIA-treated knees from WT and 
TASTPM mice displayed thinning cartilage and loss of proteoglycan staining (Fig. 3B and D; 
shown with arrowheads). Quantitative analysis revealed trends of increased knee joint cartilage 
degradation (not significant, p > 0.05) in both TASTPM and WT mice 4 weeks post MIA 
administration compared to their respective controls (Fig. 3E). 
MIA-induced synovial inflammation 
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Microscopic examination of the knee joint using H&E, 28 days post MIA injection 
demonstrated sparse distribution of haematoxylin positive nuclei within the synovial 
membrane of saline-treated knees from both WT and TASTPM mice (Fig. 4A and C). MIA-
treated knees from WT and TASTPM mice displayed thickening of the synovial membrane 
and abundant haematoxylin positive cell nuclei within the synovial membrane (Fig. 4B and D). 
Attenuated MIA-induced spinal microgliosis in TASTPM mice 
Spinal changes associated with intra-articular injection of MIA include a microglial response 
in the ipsilateral dorsal horn associated with an increased primary afferent input (Ogbonna et 
al., 2013). Therefore, immunohistochemical analysis of microglial response in the spinal cord 
28 days after MIA administration was performed. Intra-articular injection of MIA in WT mice 
was associated with a significant increase in IBA1 expressing microglia within the ipsilateral 
dorsal horn compared to their respective saline controls (Fig. 5A-B and E).  However, 
TASTPM mice injected with MIA did not display any change in the number of IBA1 labelled 
cells in the ipsilateral dorsal horn compared to their respective saline control mice (Fig. 5C-D 
and E). Furthermore, phosphorylated p38 in IBA1-immunopositive microglia was significantly 
higher in ipsilateral dorsal horn of MIA-compared to saline-treated WT mice, with no alteration 
evident in TASTPM (Fig. 5A-D and F). The MIA injected TASTPM exhibit a trend to lower 
frequency of p-p38 in IBA1 immunopositive cells in the ipsilateral dorsal horn, although not 
significant. As expected, no contralateral changes were observed in either WT or TASTPM 
spinal cords (Fig. 5E and F) as significant microgliosis in the spinal cord is only observed in 
spinal cords of 12 month-old TASTPM mice (Aman et al., 2016).  
Increased opioidergic activity underlying impaired MIA-induced mechanical 
hypersensitivity in TASTPM 
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MIA induced mechanical hypersensitivity was evident in TASTPM which partially recovered 
during the late phase of the disease. Having established previously (Aman et al., 2016), 
elevated opioidergic tone contribute to reduced nociceptive sensitivity to acute noxious 
stimulation in TASTPM mice, we examined the contribution this system in impairment of 
chronic pain-like behaviour. Systemic administration of naloxone, an opioid antagonist, 
unmasked the recovery of mechanical hypersensitivity in TASTPM as illustrated by a 
significant decrease in mechanical threshold values to comparable levels of that in WT mice 
three weeks after MIA administration (Fig. 6A). Naloxone did not affect the mechanical 
withdrawal thresholds in the contralateral hind paw of WT and TASTPM mice (Fig. 6B). 
Biochemical EIA analysis of the opioid peptide, -endorphin, revealed significantly elevated 
plasma levels in the TASTPM mice compared to WT four weeks after intra-articular MIA 
injection (Fig. 6C). Moreover, we were able to demonstrate a significant positive relationship 
between the ipsilateral mechanical paw withdrawal thresholds on day 28 with the plasma 
concentrations of β-endorphin (R2 = 0.589, p < 0.05) (Fig. 6D). Hence these data reinforce the 
notion that an increased endogenous opioidergic tone may underlie the altered behaviour 
response to chronic OA pain in the TASTPM model of AD. 
Altered analgesic responses in TASTPM following MIA administration 
Reversal of mechanical hypersensitivity was performed between day 0 – day 7 and day 10 – 
day 28 to represent the early/inflammatory and established late stage of the disease 
respectively. As weight bearing asymmetry was absent in the MIA injected transgenic 
TASTPM mice; we considered robust, and therefore only examined, reversal of mechanical 
hypersensitivity as a measure of analgesia. 
Celecoxib, a NSAID, was demonstrated to induce similar level of analgesia in both the WT 
and TASTPM mice during the early inflammatory phase (WT: 37% reversal of mechanical 
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hypersensitivity relative to pre-injection; TASTPM: 44%) (Fig. 7A). During the late 
established phase, the opioid agonist, morphine, induced greater level of analgesia in the 
TASTPM mice (WT: 24%; TASTPM: 59%) (Fig. 7B). Whilst, during the same phase 
gabapentin, an anti-epileptic drug, failed to have any analgesic effect in TASTPM (WT: 40%; 
TASTPM: 8%) (Fig. 7C). Interestingly, paracetamol (WT: 10.9% ± 5.7%; TASTPM: 21.9% ± 
10.4%) failed to induce analgesia in MIA injected WT and TASTPM mice during the 
established phase of OA pain (Fig. 7D). 
Collectively these data highlight that drugs that induce analgesia in MIA-injected WT mice 
does not necessarily have the same impact in the TASTPM model of AD. Therefore, indicating 
towards a possible alteration in nociceptive processing in chronic OA pain in the model of AD. 
Specifically, these results suggest that there is an attenuated pain-like behaviour in response to 
MIA-induced OA pain exhibited by the TASTPM transgenic mouse model of AD, which 
correlates with disruption in the opioidergic system in parallel with blunted central 
sensitisation. 
Discussion 
In this study, we report an absence of MIA-induced weight asymmetry and partial recovery of 
mechanical hypersensitivity in the TASTPM mouse model of AD. Histological and 
biochemical analysis revealed elevated opioidergic tone in parallel with diminished MIA-
induced microgliosis in the TASTPM spinal dorsal horn, despite similar knee joint pathology 
in comparison to MIA-injected WT mice. This highlight a level of discrepancy between joint 
pathology and presentation of pain as clinical symptoms in OA (Hannan et al., 2000).  
Furthermore, administration of NSAID attenuated mechanical hypersensitivity in TASTPM as 
effectively as in WT. However, changes in analgesic response during the established phase of 
MIA-induced OA pain were illustrated by increased analgesic effect of morphine but an 
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inability of gabapentin to attenuate mechanical hypersensitivity in the transgenic TASTPM 
mice. Therefore, our results provide support for disruption in the opioidergic system and 
contribution of central plasticity mechanisms to OA pain for the attenuated persistent pain-like 
behaviour exhibited by TASTPM mice. 
The MIA model of OA recapitulates multiple components of human OA disease progression, 
symptoms, and associated pathology (Gregory et al., 2013). As expected, an intra-articular 
injection of MIA induced immediate onset of mechanical allodynia and weight asymmetry in 
WT mice (Ogbonna et al., 2013). These behavioural outcome measures are representation of 
referred allodynia and ongoing pain, respectively. In contrast, TASTPM mice did not display 
any sign of weight bearing asymmetry and exhibited a partial recovery of mechanical 
hypersensitivity from 14 days following administration of MIA, suggesting possible difference 
in the mechanisms underlying spontaneous and evoked pain in the TASTPM mice. However, 
mechanical hypersensitivity at 3 days after MIA injection was comparable in TASTPM and 
WT mice. This observation is in line with our previous findings that show the development of 
hypersensitivity in the carrageenan model of peripheral pain does not differ between WT and 
TASTPM mice (Aman et al., 2016).  
Despite these behavioural observations, knee joint pathology in the form of degradation of 
articular cartilage accompanied by inflammation in the synovial membrane were exhibited by 
both the TASTPM and WT mice four-weeks post MIA administration. Intra-articular 
administration of MIA has been shown to display mechanical hypersensitivity in absence of 
weight bearing deficits in a dose-dependent manner, despite the knee joint pathologies (Nwosu 
et al., 2016; Ogbonna et al., 2013). Therefore, mechanical hypersensitivity and absence of 
ongoing pain exhibited by the transgenic model of AD may suggest a possible alteration of 
central plasticity mechanisms of MIA induced OA pain. 
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In fact, immunohistochemical analysis revealed lack of spinal microglial response exhibited 
by MIA injected TASTPM mice in comparison to WT. Increase in spinal microglia is known 
to play an important role in central sensitisation, as attenuation of microglial activation have 
been shown to correlate with reduced pain-like behaviours in the neuropathic (partial nerve 
ligation) and inflammatory (zymosan) models of chronic pain (Clark et al., 2007; Staniland et 
al., 2010). Microglia activation in the spinal cord is known to play a critical component of 
chronic pain development. Spinal microgliosis (IBA1 immunopositive cells that also express 
p-p38) in the dorsal horn correlated with decrease in grip force strength and increase in 
mechanical hypersensitivity in models of OA and rheumatoid arthritis, respectively (Clark et 
al., 2012; Lee et al., 2011; Nieto et al., 2016). Thus, diminished spinal microgliosis in TASTPM 
mice supports the notion that an alteration in the central spinal mechanisms may contribute to 
the alteration in persistent pain-like behaviour exhibited by this model of AD. 
In addition, administration of the anti-epileptic drug gabapentin resulted in reversal of MIA-
induced mechanical allodynia in only the WT group, as expected (Fernihough et al., 2004; 
Ivanavicius et al., 2007). In contrast, it failed to have any impact in MIA-injected TASTPM 
mice. Gabapentin has been widely reported for treatment of neuropathic pain; with some 
evidence in OA (Epstein and Childers 1998; Rosner et al., 1996). Elevated α2δ1 subunit mRNA 
expression in the DRGs and dorsal spinal cord of animal models of neuropathic pain (spinal 
nerve ligation) and OA (MIA) have been reported (Rahman et al., 2009; Zhou and Luo 2014). 
Gabapentin is likely to modulate activity of voltage-gated calcium channels, probably through 
its ability to bind to α2δ1 subunit. As a result, decrease in neurotransmitter release and 
propagation of action potential in nociceptive neurons which in turn dampens nociceptive 
neuronal hyper-excitability (Hayashida et al., 2008; Kukkar et al., 2013; Ossipov et al., 2010). 
These findings coupled with the diminished spinal microgliosis in the transgenic TASTPM 
mice following MIA injection suggest a possibility of blunted spinal central sensitisation, 
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which may underlie the impaired persistent-pain like behaviour exhibited by the TASTPM 
model of AD. 
Furthermore, biochemical and pharmacological assessment indicated that the endogenous 
opioid may underlie the partial recovery of mechanical hypersensitivity in TASTPM following 
MIA administration, as illustrated by an increase in plasma β-endorphin concentration and the 
ability of systemic administration of opioid receptor antagonist naloxone to unmask MIA-
induced mechanical hypersensitivity. Endogenous opioids may block nociceptive transmission 
via multiple mechanisms including actions on the mu opioid receptors located in the periphery, 
spinal cord, and the brain (cortical and sub-cortical regions) (Stein et al., 2003).  Synthesis of 
β-endorphin is carried out primarily in the anterior pituitary gland from its precursor protein 
proopiomelanocortin (POMC). It can be regulated by the hypothalamic–pituitary–adrenal axis 
through the corticotroponin-releasing hormone (CRH) release from the hypothalamus in 
response to stress and/or pain, which signals for cleavage of POMC to generate β-endorphin 
opioid peptides (Sprouse-Blum et al., 2010; Stein et al., 2003). Increased CRH expression in 
AD parventricular nucleus has been associated with hyperactivity of the hypothalamic–
pituitary–adrenal axis that may underlie the elevation of opioidergic peptide synthesis, as 
observed in the transgenic TASTPM mice (Raadsheer et al., 1995; Scherder et al., 2003). 
Moreover, a positive relationship between the level of plasma β-endorphin and mechanical 
withdrawal thresholds four-weeks after MIA suggests that elevated opioidergic tone in 
TASTPM mice may be responsible for the lack of ongoing pain and partial reversal of 
mechanical hypersensitivity (anti-nociceptive) displayed post MIA.   
Opioids (i.e. morphine) are  used as an alternative for pain-relief in OA patients who cannot 
use NSAIDs or paracetamol (Nuesch et al., 2009). In WT mice, our results are in agreement 
with previous reports where similar doses resulted in reversal of MIA-induced mechanical 
hyperalgesia and tactile allodynia (Combe et al., 2004; Fernihough et al., 2004). Surprisingly, 
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the TASTPM mice not only exhibit an anti-nociceptive effect of morphine but display a 
significantly heightened response in comparison to WT. Recent evidence has demonstrated 
greater prescription of transdermal opioids (i.e. buprenorphine and fentanyl) and long-term 
usage in individuals with AD, despite significantly lower use of opioid amongst these 
individuals compared to cognitively-intact controls. The underlying reason may be difficulty 
in ingestion of oral medicine in moderate to severe AD individuals, higher risk of mortality 
and/or the transdermal opioid scheme provide with greater ease as they need to be replaced 
after 3-7 days (Achterberg et al., 2013; Hamina et al., 2017). However, the underlying 
mechanism for this observation remains elusive owing to the increased opioidergic tone 
detected in the transgenic model of AD, which would suggest a reduced sensitivity to 
exogenous opioid agonist, morphine (Smith and Yancey 2003). Therefore, these results 
implicate a possible regulation of the opioidergic system in AD. 
In addition, celecoxib reduced mechanical allodynia when administrated on day 6-7 following 
MIA injection in both TASTPM and WT groups, suggesting an early component of 
inflammatory pain in this chemically induced model (Beyreuther et al., 2007; Fernihough et 
al., 2004; Ferreira-Gomes et al., 2012; Rashid et al., 2013). These results provide evidence to 
support the notion that NSAIDs are as effective in inducing reversal of MIA-induced 
mechanical allodynia in TASTPM as in the WT group. Thus, implicating that the early 
peripheral mechanisms, in particular the inflammatory aspect of MIA administration in the 
knee joint driving increased spinal nociceptive input resulting in pain, may be shared in the 
WT and this model of AD.  
Moreover, paracetamol is often prescribed to patients for long term treatment (mild to moderate 
pain) where the adverse effects of NSAIDs raise concerns (Towheed et al., 2006). As expected, 
administration of paracetamol on day 28 post MIA failed to reverse mechanical allodynia in 
WT mice (Fernihough et al., 2004). Thus, indicating diminished analgesic potency of 
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paracetamol in late and established phase of MIA-induced OA. In the present study, we provide 
additional evidence in a model of AD, which also exhibited similar response to paracetamol as 
the non-transgenic WT group. Therefore, suggesting that paracetamol on its own may not be 
an effective pain management option in both individuals with AD and cognitively intact 
patients at advanced stages of OA. This raises further concerns as relatively greater prescription 
and/or use of paracetamol have recently been reported in individuals with cognitive impairment 
for analgesia in comparison to cognitively intact individuals, which may reflect clinical 
difficulties in assessment of pain in such population (Achterberg et al., 2013; Haasum et al., 
2011; Sandvik et al., 2016; Sandvik et al., 2014).   
In summary, systemic changes in concordance with changes within the central mechanisms of 
pain processing in this model of AD resulted in differential effectiveness of analgesics, in 
particular opioids, during the course of OA development and progression. However, we cannot 
exclude peripheral component from playing some roles and specific studies are required to 
address this possibility. Therefore, our data highlight the need to re-evaluate current treatments, 
such as opioids, or develop novel therapeutic strategies for management of pain in individuals 
with AD. 
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Figure Legends 
Fig 1: MIA-induced weight asymmetry absent in TASTPM mice 
Weight borne on ipsilateral hind limb, calculated as percentage of ipsilateral weight borne/total 
weight borne (ipsilateral + contralateral weight borne), by 6 months old TASTPM and age and 
gender-matched wild-type (WT), was monitored at regular intervals prior to (baseline, 0) and 
up to 28 days post intra-articular administration of MIA (1mg/10µl) or saline (control) into the 
left knee joint (A). Alteration in weight distribution were compared to between experimental 
groups within genotype (* * * p < 0.001) and between genotype within experimental group (# 
# p < 0.01, # # # p < 0.001) was detected using two-way repeated measures ANOVA followed 
by Student-Newman-Keuls post-hoc test. The number of male and female per experimental 
group: WT + Saline (n = 10: 5 males and 5 females); WT + MIA (n = 8: 4 males and 4 females); 
TASTPM + Saline (n = 8: 4 males and 4 females); and TASTPM + MIA (n = 10: 5 males and 
5 females). As no difference in thresholds was observed, prior to or at regular intervals post 
MIA administration, between male and female in both WT and TASTPM mice, the data were 
pooled. Data is as mean weight borne ± SEM (n = 8-10 mice per experimental group). Area 
under the curve (AUC) analysis were calculated and expressed as weight asymmetry where a 
lower value represent more severe weight asymmetry. All time is the analysis of AUC for 
baseline - day 28 (B), early phase (baseline - day 7) (C), and late phase (day 10 - day 28) (D). 
Statistical comparisons between experimental groups within genotype (* * * p < 0.001) and 
between genotype within experimental group (# # p < 0.01, # # # p < 0.001) were conducted using 
two-way ANOVA followed by Student-Newman-Keuls post-hoc test. All values are expressed 
as mean ± SEM (n = 8-10 mice per experimental group). 
Fig 2: Partial reversal of MIA-induced mechanical hypersensitivity in the ipsilateral hind 
paw of TASTPM mice 
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A representation of mechanical withdrawal responses in the ipsilateral hind paw of 6 months 
old TASTPM and age and gender matched wild-type (WT) that were measured at regular 
intervals prior to (baseline, 0) and up to 28 days post intra-articular administration of MIA 
(1mg/10µl) or saline (control) into the left knee joint (A). Alteration in behaviour compared 
between experimental groups (MIA vs. Saline) within genotype (WT or TASTPM) (* * * p < 
0.001) and between genotype (TASTPM vs. WT) within experimental group (Saline or MIA) 
(# # p < 0.01, # # # p < 0.001) was detected using two-way repeated measures analysis of variance 
(ANOVA) followed by Student-Newman-Keuls post-hoc test. The number of male and female 
per experimental group: WT + Saline (n = 10: 5 males and 5 females); WT + MIA (n = 8: 4 
males and 4 females); TASTPM + Saline (n = 8: 4 males and 4 females); and TASTPM + MIA 
(n = 10: 5 males and 5 females). As no difference in thresholds was observed, prior to or at 
regular intervals post MIA administration, between male and female in both WT and TASTPM 
mice, the data were pooled. Data is expressed as mean 50% paw withdrawal threshold (PWT) 
± SEM (n = 8-10 mice per experimental group). Area under the curve (AUC) for ipsilateral 
hind paw was calculated and expressed as allodynia index where a lower value represents more 
severe mechanical hypersensitivity. All time is the analysis of AUC for baseline - day 28 (B), 
early phase (baseline - day 7) (C), and late phase (day 10 - day 28) (D). Statistical comparisons 
between experimental groups within genotype (* * * p < 0.001) and between genotype within 
experimental group (# # # p < 0.001) were observed using two-way ANOVA followed by 
Student-Newman-Keuls post-hoc test. All values are expressed as mean AUC ± SEM (n = 8-
10 mice per experimental group). 
Fig 3: MIA-induced knee cartilage degradation  
Representation of toluidine blue staining of articular cartilage from control and MIA injected 
(ipsilateral) knee joints of wild-type (WT, A-B) and TASTPM (C-D) mice 28 days post MIA. 
High magnification images for each experimental group representing the outlined box (a-d). 
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Intact articular cartilage with regular and intense staining of proteoglycans was observed in the 
control WT and TASTPM mice. Whereas, 28 days post MIA injection, degradation and loss 
of ipsilateral articular cartilage (arrowheads) was induced in both WT and TASTPM knee 
joints. The scale bar represents 200µm (A-D) and 100µm (a-d). Quantitative analysis of knee 
joint pathology 28 days post MIA injection revealed increase, yet insignificant (p > 0.05 
Student’s t-test), in cartilage degradation exhibited by both TASTPM and WT compared to 
their respective saline controls (E). Data is shown as mean ± SEM (n = 4 (2 males and 2 
females) per experimental group). 
Fig 4: MIA-induced inflammation in the synovial membrane 
Representation of haematoxylin and eosin staining (H&E) of articular cartilage from control 
and MIA injected (ipsilateral) knee joints of wild-type (WT, A-B) and TASTPM (C-D) mice 
28 days post MIA. High magnification images for each experimental group representing the 
outlined box (a-d). H&E staining displayed minimal nuclei within the synovial membrane of 
WT and TASTPM controls. However 28 days post MIA resulted in thickening of the synovial 
membrane lining and infiltration cells in the ipsilateral synovial membrane of MIA injected 
animals only (arrowheads).The scale bar represents 200µm (A-D) and 100µm (a-d). 
Fig 5: Lack of MIA-induced spinal microgliosis exhibited by TASTPM mice 
Representative images showing phospho-p38 (p-p38) expressing microglia (IBA1) in the 
dorsal horn of the spinal cord (L4-L5) 28 days after intra-articular injection of saline (control) 
or MIA of TASTPM and age and gender-matched wild-type (WT) mice (A-D). The scale bar 
represents 200µm. Quantification of IBA1 immunopositive cells (E) and P-p38 expressing 
IBA1 cell frequency (F) was conducted in pooled L4 and L5 dorsal horn of MIA and control 
mice. WT mice exhibited significantly greater frequency of IBA1 immunopositive microglia 
in the ipsilateral dorsal horn compared to WT control ipsilateral (* p < 0.05, Student’s t-test) 
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and WT MIA contralateral, where increase in activated microglia was also evident (# p < 0.05, 
# # p < 0.01, Student’s t-test). Contrastingly no apparent changes in microglial or activated 
microglia were observable in the ipsilateral MIA injected TASTPM mice compared to neither 
TASTPM control ipsilateral nor TASTPM MIA contralateral (p > 0.05, Student’s t-test). Data 
is shown as mean ± SEM (n = 4 (2 males and 2 females) per experimental group). 
Fig 6: Increased opioidergic activity underlying impaired MIA-induced mechanical 
hypersensitivity in TASTPM 
Mechanical withdrawal responses of MIA injected mice were assessed in both hind paws, 
ipsilateral (A) and contralateral (B), prior to MIA injection (baseline). Twenty-four days post 
MIA administration, mice were administrated (i.p.) with naloxone hydrochloride (1mg/kg) and 
withdrawal thresholds were assessed in both hind paws at regular intervals prior to (Day 24) 
and up to 180 minutes post naloxone injection. Ipsilateral hind paw 50% paw withdrawal 
thresholds (PWT) on Day 24 were significantly lower than respective baseline in both genotype 
at all time points ($$$ p < 0.001). Naloxone hydrochloride injection reduced ipsilateral 
mechanical thresholds only in the TASTPM ipsilateral hind paw 30 minutes post 
administration (* p < 0.05) compared to pre-injection values. No effect of naloxone on 
mechanical thresholds was detected in wild-type (WT) ipsilateral (A). Also naloxone did not 
have any effect on the contralateral hind paws of both genotypes at any time point (B). 
Statistical analysis was conducted using two-way repeated measures ANOVA followed by 
Student-Newman-Keuls post-hoc test. The 50% PWT values a presented as mean ± SEM (n = 
6 (3 males and 3 females) mice per group). Plasma concentration of β-endorphin was 
determined by EIA 28 days post administration of MIA into the left knee joint of WT (1 male 
and 2 females) and TASTPM (2 males and 2 females) (C). MIA-injected TASTPM displayed 
significantly greater levels of plasma β-endorphin compared to WT (* p < 0.05, Student’s t-
test). Data is presented as mean ± SEM (n = 3 - 4 per experimental group). A positive 
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relationship between the level of plasma concentration of β-endorphin and ipsilateral 50% 
PWT 28 days post MIA injection was detected using linear regression (R2 = 0.589, p < 0.05) 
(D). Data plotted as individual animal plasma β-endorphin and 50% PWT observed on day 28.   
Fig 7: Altered analgesic responses in TASTPM Mice 
Mechanical withdrawal thresholds of MIA injected mice were assessed prior to and at specified 
intervals post analgesic or vehicle administration. Both wild-type (WT: 3 males and 3 females 
per treatment group) and TASTPM (4 males and 4 females per treatment group) mice exhibited 
increase of mechanical thresholds 1 hours post oral (p.o.) administration of celecoxib 
(30mg/kg) on 6-7 days post MIA injection compared to their respective vehicle (methyl 
cellulose) controls (* p < 0.05) (A). Administration of morphine (6mg/kg; s.c.), an opioid 
agonist, on 28 days after MIA injection resulted in significant reversal of mechanical 
hypersensitivity in both WT (4 males and 4 females per treatment group) and TASTPM (5 
males and 5 females per treatment group) mice (1 hour post injection; * * p < 0.01; * * * p < 
0.001) compared to their respective vehicle (saline) controls; with greater degree of analgesia 
observed in TASTPM compared to WT mice (# p < 0.05) (B). Gabapentin (60mg/kg; p.o.; 22-
24 days post MIA) was only effective in reversing MIA-induced mechanical hypersensitivity 
in WT (5 males and 3 females per treatment group) mice (* * p < 0.01; 3 hours post injection), 
with no effect detected in TASTPM (5 males and 4 females per treatment group) (p > 0.05), 
compared to their respective vehicle (dH2O) controls. The analgesic effect of gabapentin was 
significantly greater in WT mice compared to TASTPM (# # p < 0.01) (C). Paracetamol 
(300mg/kg; p.o.) was ineffective in alleviating MIA induced mechanical hypersensitivity (p > 
0.05) in both WT (Vehicle: 3 males and 3 females; Paracetamol: 3 male and 2 females) and 
TASTPM (Vehicle: 2 male and 3 females: Paracetamol: 5 males and 4 females) mice when 
administrated 28 days after MIA injection (30 minutes post injection), compared to their 
respective vehicle (saline) control group (D). Statistical analysis was conducted using two way 
30 
 
ANOVA followed by Student-Newman-Keuls post-hoc test. Data is presented as difference 
between post-dose and pre-dose 50% PWT values that are illustrated as mean ± SEM (n = 5 - 
10 mice per experimental group).  
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